A slow October sees deals in novel therapies with new technologies
Shi Yingzi · 11/28/2022
​October was another slow month for licensing deals in China, with a total, once again, of only seven. Three of them were in-licensing deals with overseas companies.
Big Pharma dominated the deals space in September
Shi Yingzi · 10/31/2022
September was a slow month in pharmaceutical licensing deals, only seven. But, despite low volume, the five deals that were disclosed amounted to a total of $2.083 billion, ranking September third below March and May in terms of deal value.
More MNCs are partnering with Chinese drugmakers in licensing deals
Shi Yingzi · 09/29/2022
August saw eight drug licensing deals, including five in-licensing agreements, an out-licensing deal and two partnerships between domestic companies.
Kidney disease drugs a hot spot for July in-licensing
Shi Yingzi · 08/18/2022
There were a total of eight drug licensing deals in China in July 2022. This includes four in-licensing agreements, two out-licensing deals and two programs between domestic companies or institutions.
June in-licensing deals in China biotech drop to a new low
Shi Yingzi · 07/28/2022
In-licensing activity in China’s biotech sector has stayed weak in the second quarter of 2022, with the number of in-licensing deals dropping to a new low in June. Cash-strapped Chinese drugmakers became more prudent in buying and sought big buyers for their assets instead.
MSD and Turning Point turn to China for big deals in May
Danni Yin · 06/30/2022
The biotech deal making space in May 2022 saw Chinese drugmakers licensing out their assets for as much as a billion dollars. MSD and Turning Point Therapeutics gained China-originated cancer drugs in deals worth $2.63 billion.
April licensing trends show Chinese biotechs expanding beyond oncology
Minhua Chu · 05/26/2022
From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China.
Adagene-Sanofi’s $2.5B deal tops March deals in China
Minhua Chu · 04/28/2022
Several early-stage out-licensing deals inked by Chinese biotech firms to carry their in-house technology platforms and pipelines to the global market marked the dealmaking space of March 2022.
Huadong Medicine lands three in-licensing deals in one month
Minhua Chu · 03/21/2022
Huadong Medicine announced a series of three in-licensing deals with a combined value of $1.667 billion, pushing the total deal value for February to $1.883 billion, edging over the $1.681 billion the previous month.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement